कंपनी का अवलोकन
Vivos Therapeutics, Inc. operates as a specialized medical technology entity focused on developing and commercializing therapeutic modalities for patients suffering from dentofacial abnormalities, obstructive sleep apnea, and snoring in adults. The company's primary offering, known as The Vivos Method, represents a distinct approach that is non-invasive, non-surgical, and does not rely on pharmaceutical intervention. This firm functions within the broader Healthcare sector, specifically targeting the Medical Devices industry, which implies a focus on tangible equipment and procedural technologies rather than biological drugs. Currently, the organization employs 262 individuals and maintains a market capitalization of $14.19M alongside an annual revenue of $17.32M. These valuation and revenue figures indicate that Vivos Therapeutics is a micro-cap entity with a relatively small market footprint, suggesting it is still in a developmental phase where scaling operations is critical for future stabilization.
वित्तीय स्वास्थ्य
The company reported a trailing twelve-month revenue of $17.32M, yet it recorded a net income loss of $17,103,000 and an EBITDA of $-15,307,000. The substantial disparity between the positive revenue figure and the deeply negative net income reveals a highly aggressive cost structure where operating expenses significantly outpace top-line generation. Free cash flow stands at $-9,380,750, indicating that the company is burning cash rapidly, which severely limits its current financial flexibility and reliance on external capital markets. Gross margin stands at 55.7%, suggesting a favorable pricing power or cost of goods control, whereas the operating margin is -69.8% and the profit margin is -98.8%, highlighting severe inefficiencies in the core business operations before tax impacts. On the balance sheet, cash holdings of $3.09M are insufficient to cover total debt obligations of $12.50M, creating a precarious liquidity position. The debt-to-equity ratio is an extreme 493.60, demonstrating that the company is highly leveraged and carries a significant financial risk profile. Furthermore, the current ratio of 0.78 indicates that current assets are less than current liabilities, signaling potential short-term liquidity challenges in meeting immediate obligations. Return on Equity is -335.5% and Return on Assets is -49.8%, metrics that reveal management is currently destroying value rather than generating returns for shareholders or utilizing assets efficiently.
मूल्यांकन आकलन
Valuation multiples for Vivos Therapeutics present a complex picture due to the lack of profitability, with a trailing P/E ratio listed as N/A and a forward P/E of -0.96. The negative forward P/E implies that the market is pricing in continued earnings contraction or a complete absence of expected earnings growth in the near term. The price-to-book ratio is 3.92, which suggests that the market is assigning a significant premium to the company's tangible assets, a valuation stance often seen in growth-oriented biotech or medtech firms despite current losses. Alternative valuation metrics such as the price-to-sales ratio of 0.82 and an EV/EBITDA of -1.32 provide context for investors analyzing revenue-generating capabilities independent of earnings quality. Regarding trading ranges, the stock has a 52-week high of $7.95 and a 52-week low of $1.08, meaning the current price sits well below the recent peak but remains elevated relative to the bottom of its annual trading range. The beta value is 6.90, indicating that the stock price is exceptionally volatile and moves with extreme intensity relative to the broader market, exposing investors to substantial price swings for every unit of market movement.
Growth & Income
Revenue growth year-over-year is reported at 75.7%, while earnings growth is N/A due to the company's persistent net losses. The divergence between strong revenue expansion and the absence of earnings growth implies that top-line momentum has not yet translated into profitability, a common trajectory for companies investing heavily in research and commercialization. As a non-dividend payer, the company has a dividend yield of N/A and a payout ratio of 0.0%, confirming that all available earnings or cash reserves are being reinvested into operations rather than distributed to shareholders. This reinvestment strategy is necessary given the negative free cash flow, as the company cannot sustainably support dividend payments while attempting to cover its substantial debt obligations and operational deficits. The overall growth and income profile reflects a high-risk, high-volatility investment vehicle driven by revenue expansion rather than income generation or shareholder distributions.